ENElizabeth H. Nardin

Elizabeth H. Nardin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elizabeth H. Nardin has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Giane A. Oliveira

    Department of Medical Parasitology, New York University School of Medicine, 341 East 25th St., New York, NY 10010, USA

    4 shared publications
  • J. Mauricio Calvo-Calle

    Department of Medical Parasitology,1 Department of Pathology, Michael Hiedelberger Division of Immunology, New York University School of Medicine, New York, New York2

    4 shared publications
  • Annette Schmidt

    Department of Medical Parasitology, New York University School of Medicine, New York, New York,1 Apovia, Inc., San Diego, California,2 Malaria Vaccine Initiative, Program for Appropriate Technologies in Health, Rockville, Maryland,3 Department of Clinical Pharmacology, University Hospital Tuebingen, Tuebingen, Germany,4 Apovia, Inc., Martinsried, Germany,5 Institute for Tropical Medicine, Department of Human Parasitology, University of Tuebingen6

    2 shared publications
  • George B. Thornton

    Pain Therapeutics, Inc., Austin, Texas, United States of America

    2 shared publications
  • Kristiane Wetzel

    Department of Medical Parasitology, New York University School of Medicine, New York, New York,1 Apovia, Inc., San Diego, California,2 Malaria Vaccine Initiative, Program for Appropriate Technologies in Health, Rockville, Maryland,3 Department of Clinical Pharmacology, University Hospital Tuebingen, Tuebingen, Germany,4 Apovia, Inc., Martinsried, Germany,5 Institute for Tropical Medicine, Department of Human Parasitology, University of Tuebingen6

    2 shared publications
  • Adrian John Frederick Luty

    Paris University

    1 shared publication

Latest Publications

  • Class II-Restricted Protective Immunity Induced by Malaria Sporozoites

    by Giane A. Oliveira, Kota Arun Kumar, J. Mauricio Calvo-Calle, Caroline Othoro, David Altszuler, Victor Nussenzweig, Elizabeth H. Nardin

    The irradiated-sporozoite vaccine elicits sterile immunity againstPlasmodiumparasites in experimental rodent hosts and human volunteers. Based on rodent malaria models, it has been proposed that CD8+T cells are the key protective effector mechanism required in sporozoite-induced immunity. To investigate the role of class II-restricted immunity in protective immunity, we immunized β2-microglobulin knockout (β2M−/−) mice with irradiatedPlasmodium yoeliiorP. bergheisporozoites. Sterile immunity was obtained in the CD8+-T-cell-deficient mice immunized with eitherP. bergheiorP. yoeliisporozoites. β2M−/−mice with the BALB/c (H-2d) genetic background as well as those with the C57BL (H-2b) genetic background were protected. Effector mechanisms included CD4+T cells, mediated in part through the production of gamma interferon, and neutralizing antibodies that targeted the extracellular sporozoites. We conclude that in the absence of class I-restricted CD8+T cells, sporozoite-induced protective immunity can be effectively mediated by class II-restricted immune effector mechanisms. These results support efforts to develop subunit vaccines that effectively elicit high levels of antibody and CD4+T cells to targetPlasmodiumpreerythrocytic stages.


  • Open Access

    A Linear Peptide Containing Minimal T- and B-Cell Epitopes ofPlasmodium falciparumCircumsporozoite Protein Elicits Protection against Transgenic Sporozoite Challenge

    by J. Mauricio Calvo-Calle, Giane A. Oliveira, Carol Othoro Watta, Jonathan Soverow, Carlos Parra-Lopez, Elizabeth H. Nardin

    An effective malaria vaccine is needed to address the public health tragedy resulting from the high levels of morbidity and mortality caused byPlasmodiumparasites. The first protective immune mechanism identified in the irradiated sporozoite vaccine, the “gold standard” for malaria preerythrocytic vaccines, was sporozoite-neutralizing antibody specific for the repeat region of the surface circumsporozoite (CS) protein. Previous phase I studies demonstrated that a branched peptide containing minimal T- and B-cell epitopes ofPlasmodium falciparumCS protein elicited antirepeat antibody and CD4+-T-cell responses comparable to those observed in volunteers immunized with irradiatedP. falciparumsporozoites. The current study compares the immunogenicity of linear versus tetrabranched peptides containing the same minimal T- and B-cell epitopes, T1BT*, comprised of a CS-derived universal Th epitope (T*) synthesized in tandem with the T1 and B repeats ofP. falciparumCS protein. A simple 48-mer linear synthetic peptide was found to elicit antisporozoite antibody and gamma interferon-secreting T-cell responses comparable to the more complex tetrabranched peptides in inbred strains of mice. The linear peptide was also immunogenic in outbred nonhuman primates (Aotus nancymaae), eliciting antibody titers equivalent to those induced by tetrabranched peptides. Importantly, the 48-mer linear peptide administered in adjuvants suitable for human use elicited antibody-mediated protection against challenge with rodent malaria transgenic sporozoites expressingP. falciparumCS repeats. These findings support further evaluation of linear peptides as economical, safe, and readily produced malaria vaccines for the one-third of the world's population at risk of malaria infection.


  • Open Access

    Safety and Enhanced Immunogenicity of a Hepatitis B Core ParticlePlasmodium falciparumMalaria Vaccine Formulated in Adjuvant Montanide ISA 720 in a Phase I Trial

    by Giane A. Oliveira, Kristiane Wetzel, J. Mauricio Calvo-Calle, Ruth Nussenzweig, Annette Schmidt, Ashley Birkett, Filip Dubovsky, Eveline Tierney, Christoph H. Gleiter, Gabriele Boehmer, et al.

    Highly purified subunit vaccines require potent adjuvants in order to elicit optimal immune responses. In a previous phase I trial, an alum formulation of ICC-1132, a malaria vaccine candidate comprising hepatitis B core (HBc) virus-like particle containingPlasmodium falciparumcircumsporozoite (CS) protein epitopes, was shown to elicitPlasmodium falciparum-specific antibody and cellular responses. The present study was designed as a single-blind, escalating-dose phase I trial to evaluate the safety and immunogenicity of single intramuscular doses of ICC-1132 formulated in the more potent water-in-oil adjuvant Montanide ISA 720 (ICC-1132/ISA 720). The vaccine was safe and well tolerated, with transient injection site pain as the most frequent complaint. All vaccinees that received either 20 μg or 50 μg of ICC-1132/ISA 720 developed antiimmunogen and anti-HBc antibodies. The majority of volunteers in these two groups developed sporozoite-specific antibodies, predominantly of opsonizing immunoglobulin G subtypes. Peak titers and persistence of parasite-specific antibody following a single injection of the ISA 720 formulated vaccine were comparable to those obtained following two to three immunizations with alum-adsorbed ICC-1132. Peripheral blood mononuclear cells of ICC-1132/ISA 720 vaccinees proliferated and released cytokines (interleukin 2 and gamma interferon) when stimulated with recombinantP. falciparumCS protein, and CS-specific CD4+T-cell lines were established from volunteers with high levels of antibodies to the repeat region. The promising results obtained with a single dose of ICC-1132 formulated in Montanide ISA 720 encourage further clinical development of this malaria vaccine candidate.


  • Open Access

    Phase I Testing of a Malaria Vaccine Composed of Hepatitis B Virus Core Particles ExpressingPlasmodium falciparumCircumsporozoite Epitopes

    by Elizabeth H. Nardin, Giane A. Oliveira, J. Mauricio Calvo-Calle, Kristiane Wetzel, Carolin Maier, Ashley J. Birkett, Pramod Sarpotdar, Michael L. Corado, George B. Thornton, Annette Schmidt

    We report the first phase I trial to assess the safety and immunogenicity of a malaria vaccine candidate, ICC-1132 (Malarivax), composed of a modified hepatitis B virus core protein (HBc) containing minimal epitopes of thePlasmodium falciparumcircumsporozoite (CS) protein. When expressed inEscherichia coli, the recombinant ICC-1132 protein forms virus-like particles that were found to be highly immunogenic in preclinical studies of mice and monkeys. Twenty healthy adult volunteers received a 20- or a 50-μg dose of alum-adsorbed ICC-1132 administered intramuscularly at 0, 2, and 6 months. The majority of volunteers in the group receiving the 50-μg dose developed antibodies to CS repeats as well as to HBc. Malaria-specific T cells that secreted gamma interferon were also detected after a single immunization with ICC-1132-alum. These studies support ICC-1132 as a promising malaria vaccine candidate for further clinical testing using more-potent adjuvant formulations and confirm the potential of modified HBc virus-like particles as a delivery platform for vaccines against other human pathogens.